Reason for study termination | Placebo (n (%)) | Olsalazine (n (%)) |
Completed study | 75 (46.6) | 57 (34.1) |
Relapse (CDAI) | 42 (26.1) | 40 (24.0) |
Clinical relapse | 17 (10.6) | 15 (9.0) |
Serious adverse events | 1 (0.6) | 2 (1.2) |
Intolerable adverse events | 10 (6.2) | 33 (19.8) |
Disallowed concomitant medication | 2 (1.2) | 4 (2.4) |
Patient consent withdrawn | 3 (1.9) | 6 (3.6) |
Other protocol violation | 3 (1.9) | 4 (2.4) |
Other | 2 (1.2) | 1 (0.6) |
Unknown | 1 (0.6) | |
Total reporting | 161 (100) | 167 (100) |
CDAI, Crohn's disease activity index.